SynthesisJournal of Crohn's & colitis2026
The predictive value of intestinal ultrasound for treatment response in inflammatory bowel disease: a systematic review and pooled data analysis.
Synthesis in Journal of Crohn's & colitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Editorial: Risankizumab in Refractory Crohn's Disease-From Real-World Effectiveness to Strategic Positioning and Early Monitoring.Alimentary pharmacology & therapeutics · 2026Article
- Integrating Intestinal Ultrasound in the Personalized Management of IBD.Journal of personalized medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIntestinal ultrasound (IUS) is a promising tool for predicting treatment response in inflammatory bowel disease (IBD). We aimed to systematically review existing literature on the predictive value of IUS for treatment response.
methodsA literature search was performed until May 2025. We included articles assessing treatment response in IBD using IUS. Data were analyzed separately for Crohn's Disease (CD), ulcerative colitis (UC) and acute severe ulcerative colitis (ASUC). Pooled data analysis was performed for bowel wall thickness (BWT) in CD patients starting anti-TNF (tumor necrosis factor).
resultsIn total, 31 articles were included (18 CD, 9 UC, and 4 ASUC). In 8/10 CD studies, IUS at week 4-8 could distinguish future responders, with BWT change ranging from -43% to -14.6% in responders vs. -14% to + 2% in nonresponders. In the pooled data analysis of anti-TNF-treated CD patients (n = 236) a 23% decrease from baseline at week 4-8 (area under the receiver operating characteristic curve [AUROC] 0.82) and 27% decrease at week 12-16 (AUROC 0.78) could predict future response. In 2/2 UC studies, IUS after 4-8 weeks could predict future endoscopic remission vs. non-remission with a decrease in BWT ranging from -55% to -49% vs. -38% to -17% respectively. In ASUC, change in BWT after 1-3 days could predict need for salvage therapy (-34% vs. -10%).
conclusionsIntestinal ultrasound predicts response at an early stage after treatment initiation, both in CD as well as in UC. In anti-TNF-treated CD patients, 23% and 27% decrease in BWT after 4-8 weeks and 12-16 weeks of treatment initiation predicts outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.